Research EyePoint shares plummet after phase 3 stumble for AMD drug-device combo DuravyuBy Healthcare Propulsion StaffAugust 17, 20260 EyePoint’s stock was down more than 70% Monday after its experimental treatment for wet age-related macular degeneration (wAMD) missed on…
